相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
James L. Gulley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
David J. Byun et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
Giulia Viale et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
James L. Gulley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Towards personalized tumor markers
Vathany Kulasingam et al.
NPJ PRECISION ONCOLOGY (2017)
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Janice M. Mehnert et al.
CLINICAL CANCER RESEARCH (2017)
Autoantibodies: Opportunities for Early Cancer Detection
Isabel K. Macdonald et al.
TRENDS IN CANCER (2017)
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Alexander Faje
PITUITARY (2016)
Autoantibody Production in Cancer-The Humoral Immune Response toward Autologous Antigens in Cancer Patients
P. Zaenker et al.
AUTOIMMUNITY REVIEWS (2016)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain et al.
CANCER TREATMENT REVIEWS (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
Jianda Yuan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
[Anonymous]
EBIOMEDICINE (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Delineating monoclonal antibody specificity by mass spectrometry
Dimitrios Korbakis et al.
JOURNAL OF PROTEOMICS (2015)
Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer
Victoria Doseeva et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma
Yu Hong et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Classifying Patients for Breast Cancer by Detection of Autoantibodies against a Panel of Conformation-Carrying Antigens
Rick L. Evans et al.
CANCER PREVENTION RESEARCH (2014)
Present and future of cancer biomarkers
Eleftherios P. Diamandis
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2014)
A repository for rare tumor markers?
Eleftherios P. Diamandis
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2014)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest With Ipilimumab Detailed Safety Analysis From a Phase 3 Trial in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
CANCER (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy
L. Qin et al.
BLOOD CANCER JOURNAL (2013)
Tumor-associated autoantibodies as diagnostic and prognostic biomarkers
Chang-Kyu Heo et al.
BMB REPORTS (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
Serena S. Kwek et al.
JOURNAL OF IMMUNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Personalized Medicine and Cancer
Mukesh Verma
JOURNAL OF PERSONALIZED MEDICINE (2012)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nicholas B. La Thangue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Cancer immunotherapy - revisited
W. Joost Lesterhuis et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Gene Signature in Melanoma Associated With Clinical Activity A Potential Clue to Unlock Cancer Immunotherapy
Thomas F. Gajewski et al.
CANCER JOURNAL (2010)
Autoantibodies to Tumor-Associated Antigens as Cancer Biomarkers
P. V. Belousov et al.
CURRENT MOLECULAR MEDICINE (2010)
Seromic profiling of ovarian and pancreatic cancer
Sacha Gnjatic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Predictive and prognostic molecular markers for cancer medicine
Sunali Mehta et al.
Therapeutic Advances in Medical Oncology (2010)
A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth
R. Bei et al.
CANCER LETTERS (2009)
Serum autoantibodies as biomarkers for early cancer detection
Hwee Tong Tan et al.
FEBS JOURNAL (2009)
Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy
Marianna Sabatino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The sentinel within: Exploiting the immune system for cancer biomarkers
KS Anderson et al.
JOURNAL OF PROTEOME RESEARCH (2005)
An efficient proteomics-based approach for the screening of autoantibodies
L Canelle et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck
MF Madrid et al.
CANCER DETECTION AND PREVENTION (2004)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Protein microarrays: Promising tools for proteomic research
MF Templin et al.
PROTEOMICS (2003)
Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells
MH Hansen et al.
JOURNAL OF IMMUNOLOGY (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
